Skip to Main Content

Paper Details

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
JAMA Oncol
17
2023
B-cell, Cancer and Leukemia, ERBB2, ERBB2/, HER2, HER2-Positive Breast Cancer, HER2-enriched subtype, HER2-positive breast cancer, Immune-Related Gene Expression Signatures, PAM50, PAMELA, RNA, T cells, TILs, Tumor-Infiltrating Lymphocytes, immune, immune signatures, immune-related gene expression signatures, immunoglobulin G, lapatinib, paclitaxel, patients, trastuzumab, tumor, tumor-infiltrating lymphocytes, tumors, women
Author NameAffiliation
Tomás PascualLineberger Comprehensive Cancer Center, University of North Carolina
Tomás Pascual
Tomás PascualAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS)
Tomás PascualHospital Clinic de Barcelona
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina
Katherine A HoadleyUniversity of North Carolina
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina
Katherine A HoadleyUniversity of North Carolina
Ian E KropYale Cancer Center
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina
Charles M PerouUniversity of North Carolina
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina
Lisa A CareyUniversity of North Carolina at Chapel Hill
  • 1 - 13

Datasets

Release 1.2